Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Delay in the Licensing of Protozoal Vaccines: A Comparative History
M Palatnik, Dirlei Nico
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine
Diana Souza de Oliveira, Maykelin Fuentes Zaldívar, Ana Alice Maia Gonçalves, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 271-271
Open Access | Times Cited: 9
Characterization of a new Leishmania major strain for use in a controlled human infection model
Helen Ashwin, Jovana Sádlová, Barbora Vojtková, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 44
Pre-Erythrocytic Vaccines against Malaria
Camila Marques-da-Silva, Kristen Peissig, Samarchith P. Kurup
Vaccines (2020) Vol. 8, Iss. 3, pp. 400-400
Open Access | Times Cited: 34
Sterol profiling of Leishmania parasites using a new HPLC-tandem mass spectrometry-based method and antifungal azoles as chemical probes reveals a key intermediate sterol that supports a branched ergosterol biosynthetic pathway
Mei Feng, Yiru Jin, Sihyung Yang, et al.
International Journal for Parasitology Drugs and Drug Resistance (2022) Vol. 20, pp. 27-42
Open Access | Times Cited: 20
Tratamento da leishmaniose, limitações da terapêutica atual e a necessidade de novas alternativas: Uma revisão narrativa
Alexandre Silva Santiago, Samuel Silva da Rocha Pita, Elisalva Teixeira Guimarães
Research Society and Development (2021) Vol. 10, Iss. 7, pp. e29510716543-e29510716543
Open Access | Times Cited: 26
Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis
Aline Silva Barreto, Mariana Nobre Farias de Franca, Teresa Reis, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Thio- and selenosemicarbazones as antiprotozoal agents against Trypanosoma cruzi and Trichomonas vaginalis
Alexandra Ibáñez‐Escribano, Cristina Fonseca‐Berzal, Mónica Martínez-Montiel, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 781-791
Open Access | Times Cited: 16
A state-of-the-art methodology for high-throughput in silico vaccine discovery against protozoan parasites and exemplified with discovered candidates for Toxoplasma gondii
Stephen J. Goodswen, Paul Kennedy, John Ellis
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Dimethyl-Dioctadecyl-Ammonium Bromide/Poly(lactic acid) Nanoadjuvant Enhances the Immunity and Cross-Protection of an NM2e-Based Universal Influenza Vaccine
Yuan Gao, Shulan Han, Funa Lu, et al.
ACS Nano (2024) Vol. 18, Iss. 20, pp. 12905-12916
Closed Access | Times Cited: 3
Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis
Devika M. Varma, Elizabeth A. Redding, Eric M. Bachelder, et al.
ACS Biomaterials Science & Engineering (2020) Vol. 7, Iss. 5, pp. 1725-1741
Open Access | Times Cited: 19
Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases
José Carlos Solana, Javier Moreno, Salvador Iborra, et al.
Trends in Parasitology (2021) Vol. 38, Iss. 4, pp. 316-334
Open Access | Times Cited: 17
Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
Cal Koger-Pease, Dilhan J. Perera, Momar Ndao
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 334-334
Open Access | Times Cited: 7
Sexual Development in Non-Human Parasitic Apicomplexa: Just Biology or Targets for Control?
Teresa Cruz‐Bustos, Anna Sophia Feix, Bärbel Ruttkowski, et al.
Animals (2021) Vol. 11, Iss. 10, pp. 2891-2891
Open Access | Times Cited: 14
Natural resources to control COVID-19: could lactoferrin amend SARS-CoV-2 infectivity?
Ehab H. Mattar, Fatma Elrashdy, Hussein A. Almehdar, et al.
PeerJ (2021) Vol. 9, pp. e11303-e11303
Open Access | Times Cited: 11
Oral immunization with heat-inactivated Mycobacterium bovis reduces local parasite dissemination and hepatic granuloma development in mice infected with Leishmania amazonensis
Elisa Ferreras‐Colino, Inmaculada Moreno, Christian Gortázar, et al.
Research in Veterinary Science (2023) Vol. 162, pp. 104963-104963
Closed Access | Times Cited: 4
O desenvolvimento de vacinas contra as doenças tropicais negligenciadas
Expedito José de Albuquerque Luna, Sérgio Roberto de Souza Leão da Costa Campos
Cadernos de Saúde Pública (2020) Vol. 36, Iss. suppl 2
Open Access | Times Cited: 11
Properties of virulence emergence ofLeishmania infantumisolates fromPhlebotomus perniciosuscollected during the human leishmaniosis outbreak in Madrid, Spain. Hepatic histopathology and immunological parameters as virulence markers in the mouse model
Alicia Mas, Abel Martínez‐Rodrigo, José A. Orden, et al.
Transboundary and Emerging Diseases (2020) Vol. 68, Iss. 2, pp. 704-714
Open Access | Times Cited: 10
What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist
M Palatnik
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 10
A clinical study to optimise a sand fly biting protocol for use in a controlled human infection model of cutaneous leishmaniasis (the FLYBITE study)
Vivak Parkash, Helen Ashwin, Jovana Sádlová, et al.
Wellcome Open Research (2021) Vol. 6, pp. 168-168
Open Access | Times Cited: 9
Vaccines for Canine Leishmaniasis
Eduardo Antônio Ferraz Coelho, Myron Christodoulides
Springer eBooks (2023), pp. 281-306
Closed Access | Times Cited: 2
CpG-adjuvanted virus-like particle vaccine induces protective immunity against Leishmania donovani infection
Keon-Woong Yoon, Ki‐Back Chu, Gi-Deok Eom, et al.
The Journal of Infectious Diseases (2024)
Closed Access
Characterization of a newLeishmania majorisolate for use in a controlled human infection model
Helen Ashwin, Jovana Sádlová, Barbora Vojtková, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 1
Toward New Antileishmanial Compounds: Molecular Targets for Leishmaniasis Treatment
Hüseyin İstanbullu, Gülşah Bayraktar
IntechOpen eBooks (2022)
Open Access | Times Cited: 1
Pyridoxal Kinase of Disease-causing Human Parasites: Structural and Functional Insights to Understand its Role in Drug Discovery
Insaf Ahmed Qureshi, Mayank Saini, Sayanna Are
Current Protein and Peptide Science (2022) Vol. 23, Iss. 4, pp. 271-289
Closed Access | Times Cited: 1
Evolution and development of vaccines against major human infections
Utkarsha Sahu, Prashant Khare
Elsevier eBooks (2022), pp. 17-30
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top